Zacks Investment Research upgraded shares of Regulus Therapeutics (NASDAQ:RGLS) from a hold rating to a buy rating in a report published on Friday morning, Zacks.com reports. Zacks Investment Research currently has $0.75 price objective on the biopharmaceutical company’s stock.
According to Zacks, “Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company’s products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. “
A number of other brokerages have also recently weighed in on RGLS. Needham & Company LLC restated a hold rating on shares of Regulus Therapeutics in a research report on Tuesday, August 13th. Wedbush restated a hold rating and issued a $1.00 price target on shares of Regulus Therapeutics in a research report on Thursday, May 16th. Finally, ValuEngine upgraded Regulus Therapeutics from a sell rating to a hold rating in a research report on Thursday, August 1st. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Regulus Therapeutics currently has an average rating of Hold and a consensus target price of $1.08.
Regulus Therapeutics (NASDAQ:RGLS) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.24. Regulus Therapeutics had a negative return on equity of 186,717.70% and a negative net margin of 396.84%. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $2.50 million. Analysts forecast that Regulus Therapeutics will post -2.04 EPS for the current year.
A number of institutional investors have recently bought and sold shares of RGLS. NEA Management Company LLC increased its position in Regulus Therapeutics by 124.1% during the 2nd quarter. NEA Management Company LLC now owns 2,052,455 shares of the biopharmaceutical company’s stock worth $2,566,000 after purchasing an additional 1,136,704 shares in the last quarter. EcoR1 Capital LLC purchased a new stake in Regulus Therapeutics during the 2nd quarter worth about $1,389,000. Samsara BioCapital LLC purchased a new stake in Regulus Therapeutics during the 2nd quarter worth about $1,131,000. CVI Holdings LLC purchased a new stake in Regulus Therapeutics during the 2nd quarter worth about $568,000. Finally, Virtu Financial LLC purchased a new stake in Regulus Therapeutics during the 1st quarter worth about $68,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
See Also: Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.